Samsung Bioepis Breaks into Market with PL Strategy: Will It Continue with Dupixent?
23% Sales Growth Excluding Milestone Revenues
Rapid Entry into the U.S. Insurance System with PBM PL Products
Growing Interest in Expanding PBM PL Strategy to Next-Generation Pipelines such as Dupixent
Samsung Bioepis is accelerating the transformation of its profit structure through a so-called "no-brand strategy" that leverages the private label (PL) of prescription benefit managers (PBMs), the key distribution entities in the US insurance market. By reducing its reliance on one-off milestone revenues from research and development (R&D) achievements and instead strengthening its core business competitiveness based on product sales, the company has secured greater earnings stability. There is growing interest in whether the PL strategy, which has driven changes in its earnings structure, can be expanded to next-generation pipeline products in the future.
According to the pharmaceutical and biotech industry on January 26, Samsung Bioepis's performance last year was characterized more by changes in its profit structure than by top-line growth. According to Samsung Bioepis Holdings, annual revenue last year reached 1.672 trillion won, up 9% from the previous year, but operating profit fell 14% to 375.9 billion won.
Although profitability appears to have declined on the surface, a closer look at product sales excluding milestone revenues shows that the core business's profitability actually improved. Operating profit from pure product sales was 330.8 billion won, a 101% increase from 164.5 billion won the previous year, and revenue under the same criteria rose 28%. In the fourth quarter as well, overall revenue growth was only 8%, but excluding milestone revenues, product sales increased 23% and operating profit rose 14%.
The key driver of this shift in earnings structure has been the PBM PL strategy in the US market. Last year, the company launched a Stelara biosimilar locally, supplying it under the private labels of major US PBMs, CVS Caremark and Express Scripts (ESI), rather than under the Samsung brand.
Analysts note that the company opted to utilize the distribution networks of PBMs, the main distribution channels in the US insurance market, rather than putting the manufacturer's name at the forefront. The PBM PL model can be compared to large retail chains sourcing products from manufacturers and selling them under their own private labels. When Samsung Bioepis supplies its products, PBMs lead the sales under their own brands, allowing the products to enter insurance reimbursement systems nationwide without the need for separate large-scale marketing or sales organizations.
The PBM PL structure is directly linked to increased prescription volumes. PL products often receive priority placement on insurers' formularies, improving reimbursement access. Even when the same active ingredient is prescribed, the insurance claims process often leads to a switch to the PL product, resulting in a rapid increase in prescription volumes.
The very fact that Samsung Bioepis succeeded in signing PL contracts with major US PBMs, known for their stringent standards, is seen as a milestone that has enhanced the company's external credibility. Since PBMs sell products under their own brands, they require not only low prices but also reliability in consistent quality and the ability to supply large volumes on time. Financial strength to handle potential supply disruptions after inclusion in reimbursement systems, as well as stability in long-term partnerships, are also essential requirements.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The market's attention is now focused on whether Samsung Bioepis's next-generation pipeline can continue the PBM PL strategy. One candidate mentioned in the industry is the Dupixent biosimilar. Drugs that PBMs consider as PL candidates are typically chronic disease treatments with steady prescription volumes. The larger the patient population and the greater the impact on insurance finances, the stronger the PBM's incentive to manage prescription flows through reimbursement terms. Dupixent, with global sales of approximately 24 trillion won, is considered to meet these criteria. While Stelara demonstrated the effectiveness of the PBM PL strategy in the immunology market, Dupixent is seen as a benchmark for whether the strategy can expand into the larger chronic disease market.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.